Kintara Therapeutics

$1.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.11 (+7.91%) Today
$0.00 (0.00%) As of 9:53 PM UTC after-hours

Why Robinhood?

You can buy or sell KTRA and other stocks, options, and ETFs commission-free!

About KTRA

Kintara Therapeutics, Inc. Common Stock, also called Kintara Therapeutics, is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. Its pipeline includes the VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA. The listed name for KTRA is Kintara Therapeutics, Inc. Common Stock.

CEO
Saiid Zarrabian
Employees
19
Headquarters
San Diego, California
Founded
2009
Market Cap
37.52M
Price-Earnings Ratio
Dividend Yield
Average Volume
455.76K
High Today
$1.59
Low Today
$1.38
Open Price
$1.38
Volume
1.13M
52 Week High
$1.95
52 Week Low
$0.38

Collections

KTRA Earnings

-$0.89
-$0.48
-$0.06
$0.35
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
per share
Actual
Expected May 25, Pre-Market

You May Also Like

SSKN
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure